Baird analyst Joel Beatty raised the firm’s price target on PTC Therapeutics (PTCT) to $70 from $52 and keeps an Outperform rating on the shares. The firm raised its target as they believe the value of the new Huntington’s disease collaboration with Novartis (NVS) is not yet fully priced in to the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $41 from $31 at BofA
- PTC Therapeutics price target raised to $56 from $45 at Barclays
- PTC Therapeutics’ Novartis deal expedites value creation, says Wells Fargo
- RBC upgrades PTC Therapeutics on ‘transformative’ Novartis deal
- PTC Therapeutics upgraded to Outperform from Sector Perform at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com